Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106137 | 0.82 | DGAT1 (0.33) | DGAT1CYP11B1CYP11B2 | |
| SCHEMBL21916168 | 0.76 | — | — | |
| SCHEMBL25618878 | 0.72 | CYP11B1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL21719291 | 0.72 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL22678984 | 0.72 | AAK1 (0.33) | — | |
| SCHEMBL10110581 | 0.70 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL31214086 | 0.70 | CYP11B1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL18743565 | 0.70 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL2602384 | 0.70 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL29324345 | 0.69 | P2RX3 (0.34) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | DGAT1 4779/4885CYP11B1 1978/4885CYP11B2 1963/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | DGAT1 1839/4885CYP11B1 334/4885CYP11B2 205/4885 |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | DGAT1 4779/4885CYP11B1 2090/4885CYP11B2 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.